Zavoĭkin V D, Mikhaĭlov M M, Zelia O P, Bronshteĭn A M, Firsova R A, Sokerina O A, Gerasimov I V, Gorbunov N S, Kostyrev E P
Med Parazitol (Mosk). 1995 Jul-Sep(3):32-4.
Whether the Russian praziquantel analog azinox can be widely used in the foci of opisthorchiasis was first assessed. The outpatient treatment of 7405 patients with the agent in doses of 30, 40, 60 mg/kg body weight revealed that azinox tolerance did not depend upon the intensity and degree of clinical infection signs but it was slightly worse when a dose of 60 mg/kg was given. Children virtually showed no adverse reactions, in adults their frequency was no more than 52 +/- 1.4%. The parasitological efficiency of azinox in the used doses was 96-99% in children and 82-86% in adults. There was a clinical improvement in 65% of the treated. Thus, the national drug azinox is not inferior to the imported agent bilthricide in tolerance, parasitological and clinical efficiency. Bearing in mind the equal efficiency, but the better tolerance and less cost of the drug doses of 30 and 40 mg/kg body weight, it is advisable to use them in the foci for outpatient treatment.
首次评估了俄罗斯吡喹酮类似物阿齐诺克斯（azinox）是否可在华支睾吸虫病疫源地广泛使用。用该药物以30、40、60mg/kg体重的剂量对7405例患者进行门诊治疗，结果显示阿齐诺克斯的耐受性不取决于临床感染体征的强度和程度，但给予60mg/kg剂量时耐受性略差。儿童几乎未出现不良反应，成人中不良反应发生率不超过52±1.4%。所用剂量的阿齐诺克斯对儿童的寄生虫学疗效为96 - 99%，对成人的疗效为82 - 86%。65%的治疗患者有临床改善。因此，国产药物阿齐诺克斯在耐受性、寄生虫学和临床疗效方面并不逊色于进口药物吡喹酮。考虑到疗效相同，但30和40mg/kg体重药物剂量耐受性更好且成本更低，建议在疫源地用于门诊治疗。
